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Abstract
Background: The genetic variation underlying atorvastatin (ATV) pharmacokinetics was evaluated in a Mexican
population. Aims of this study were: 1) to reveal the frequency of 87 polymorphisms in 36 genes related to drug
metabolism in healthy Mexican volunteers, 2) to evaluate the impact of these polymorphisms on ATV
pharmacokinetics, 3) to classify the ATV metabolic phenotypes of healthy volunteers, and 4) to investigate a
possible association between genotypes and metabolizer phenotypes.
Methods: A pharmacokinetic study of ATV (single 80-mg dose) was conducted in 60 healthy male volunteers.
ATV plasma concentrations were measured by high-performance liquid chromatography mass spectrometry.
Pharmacokinetic parameters were calculated by the non-compartmental method. The polymorphisms were
determined with the PHARMAchip® microarray and the TaqMan® probes genotyping assay.
Results: Three metabolic phenotypes were found in our population: slow, normal, and rapid. Six gene
polymorphisms were found to have a significant effect on ATV pharmacokinetics: MTHFR (rs1801133), DRD3 (rs6280),
GSTM3 (rs1799735), TNFα (rs1800629), MDR1 (rs1045642), and SLCO1B1 (rs4149056). The combination of MTHFR, DRD3
and MDR1 polymorphisms associated with a slow ATV metabolizer phenotype.
Conclusion: Further studies using a genetic preselection method and a larger population are needed to confirm
these polymorphisms as predictive biomarkers for ATV slow metabolizers.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12614000851662, date registered: August 8,
2014.
Keywords: Atorvastatin, Genotype phenotype association, Predictive genetic testing
Background
The drug atorvastatin (ATV) is widely prescribed to
treat hypercholesterolemia, which is a predisposing fac-
tor for developing atherosclerosis. ATV, like all statins,
acts by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme
A reductase, an essential enzyme in cholesterol
biosynthesis. ATV reduces the risk of atherosclerosis by
lowering the levels of low-density lipoprotein-bound
cholesterol [1]. ATV is administered orally, as a calcium
salt (acid form), at a dose that ranges between 10 and
80 mg/day. Once ATV is ingested, several enzymes par-
ticipate in its metabolism. The enzymes encoded by
CYP3A4 and CYP3A5 are the most important ones [2].
These enzymes transform ATV first to its lactone form
and subsequently into 2 pharmacologically active metab-
olites (2-hydroxy-ATV and 4-hydroxy-ATV) [3, 4]. Next,
ATV and its secondary metabolites are glucuronidated
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by uridine diphosphoglucuronosyltransferases (encoded
by UGT1A1 and UGT1A3) [5]. Apart from metabolic en-
zymes, carrier proteins are involved in ATV metabolism,
such as: 1) P-glycoprotein, also known as multidrug re-
sistance protein 1 (MDR1), product of ABCB1, 2) the or-
ganic anion-transporting polypeptides (OATP1B1 and
OATP1B3) encoded by SCLO1B1 and SCLO1B3, re-
spectively [6–8], and 3) the breast cancer resistance pro-
tein (BCRP2), product of ABCG2 [9, 10].
Drug performance is evaluated on two main areas:
pharmacokinetics and pharmacodynamics. The former
focuses primarily on the evaluation of absorption, distri-
bution, metabolism, and excretion processes (ADME) of
a drug; consequently, the variation in genes responsible
for this process contributes to interindividual variability
[11]. On the other hand, pharmacodynamics evaluates
biochemical and physiological effects, as well as the
mechanisms of action of a drug, i.e. it focuses on the
drug response [12]. The pharmacokinetics of ATV dis-
plays high interindividual variability of up to 30 % [13,
14]. This pharmacokinetic discrepancy reveals variations
in the ADME processes as the drug passes through the
human body [12]. Factors such as age, gender, ethnicity,
and genetic variability are involved in such interindivid-
ual differences [15, 16]. Genetic factors are responsible
for about 15 to 30 % of the interindividual variation in
metabolism, and thus in the response of each patient to
certain classes of drugs. However, for some drugs this
percentage can increase to up to 95 % [17]. These gen-
etic factors are mainly due to variations in short tandem
repeats, copy number variations, insertions and dele-
tions, and single-nucleotide polymorphisms (SNPs). The
latter is the most common source of variation [18–20].
The presence of these polymorphisms in genes involved
in the metabolism of ATV may explain its pharmacoki-
netic variability [17], since the frequency and conse-
quences also vary between different populations [21].
The aims of this study were: 1) to reveal the frequency
of 87 polymorphisms in 36 genes related to drug metab-
olism in healthy volunteers, 2) to evaluate the impact of
these polymorphisms on ATV pharmacokinetics, 3) to
classify the metabolic phenotypes for ATV, and 4) to in-




A randomized pilot study was carried out in 60 healthy
Mexican volunteers to determine ATV pharmacokinetic
parameters. A single dose of 80 mg ATV was adminis-
tered. The clinical study complied with Good Clinical
Practice standards, the guidelines of the Declarations of
Helsinki and Tokyo, and the Mexican regulations on
Bioavailability and Bioequivalence Studies (NOM-177-
SSA1-1998) [22]. Furthermore, the protocol was ap-
proved by the Research and Ethics Committee of the
pharmacokinetic study center, Ipharma S.A. (Monterrey,
Mexico). The clinical study has been registered at the
Australian New Zealand Clinical Trials Registry (regis-
tration number: ACTRN12614000851662).
Study population
Sixty four healthy male candidates from northeastern
Mexico were recruited and a written informed consent
was obtained. Inclusion criteria were: non-smoker, 18-
to-45-year old, weight ≥ 50 kg, body mass index (BMI) of
20–26 kg/m2, availability for completing the study, being
healthy. Since ATV is classified as a pregnancy category
X drug, only males were considered for the study. Can-
didates were excluded for: any abnormal lab result,
significant personal or family medical history of angio-
edema o allergies, the existence of concurrent disease,
use of prescription or over-the-counter medication or al-
cohol before enrollment, history of smoking, alcohol or
drug abuse, and incompliance or non-willingness to
complete the study. Four candidates were excluded be-
cause of the consumption of alcohol and/or substances
or an altered blood pressure. The health status of the
volunteers was confirmed by a medical history, a phys-
ical examination, an electrocardiogram (ECG), labora-
tory tests (blood count, blood chemistry, liver function
tests, and urinalysis), and seronegativity for human im-
munodeficiency virus and hepatitis B and C viruses.
Drug administration and sampling
After an overnight fast at the study center (Ipharma, S.
A.), each subject was given a single dose of 80 mg of
ATV-coated tablets (Pfizer Pharmaceuticals LLC, Caguas
Site, Caguas, PR). The volunteers were under direct
medical supervision at the study site. Venous blood
(4 mL) was collected in K2EDTA-coated Vacutainers
TM
(BD Diagnostics, Franklin Lakes, NJ, US), before ATV
administration (time 0), and at the following time points
after drug administration: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,
3.5, 4, 5, 6, 8, 12, 24, 36 and 48 h. Plasma was separated
by centrifugation (15 min at 1600 g at 4 °C) and stored
in cryovials at −80 °C until analysis, using a method vali-
dated by Ipharma S. A. [3, 23, 24].
Pharmacogenetic tests
Leukocytes were obtained from the buffy coat, and gen-
omic DNA was extracted by the alkaline lysis method
[25]. Seven multiplex polymerase chain reactions (PCRs)
amplified the desired gene regions, following a validated
protocol [26]. Screening for gene polymorphisms was
performed using the PHARMAchip® microarray (Pro-
genika, Derio, ES). This pharmacogenetic genotyping de-
vice detects, with a 99.9 % specificity and sensitivity, 85
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gene polymorphisms in 34 genes involved in drug me-
tabolism and response, including those encoding cyto-
chrome P450 enzymes, phase II metabolism enzymes,
receptors, and transporters. Amplified products were
fractionated with DNAse according to a validated
protocol [26], followed by fluorescent labeling and
hybridization of the microarray, in an automated
TECAN HS4800PRO platform (Ventana Medical Sys-
tems Inc., Tucson, AZ, US). The hybridization pattern
was revealed using the Innoscan 710 scanner (Innopsys
S.A., Carbonne, FR). Polymorphic variants were deter-
mined using PHARMAchip software V.3.2.9 [26]. Two
additional polymorphisms not included in the PHAR-
MAchip, rs2231142 (C__15854163_70) and rs4149056
(C__30633906_10), in ABCG2 and SLCO1B1 respect-
ively, were included in the study and analyzed by Real-
Time PCR system using validated Genotyping Assays
(Applied Biosystems, Foster City, CA, US) according to
the manufacturer’s instructions. Typed polymorphisms
were only includedin subsequent association studies
after having passed three quality control tests: the geno-
type call rate (>0.90 completeness to obtain 99.8 % ac-
curacy), the Hardy-Weinberg equilibrium (HWE) test
(P-value > 0.05), and the minor allele frequency (MAF)
criterion (>0.01).
Determination of ATV calcium in plasma
Proteins were eliminated from the plasma samples by add-
ing 4 volumes of acetonitrile to 100-μL samples, vortexing
(70 rpm, 4 min.), and precipitating by centrifugation
(9600 g, 10 min., 10 °C). Protein-free supernatant (300 μL)
was recovered and 5-μL samples were injected into an
Agilent 1100 high-performance liquid chromatographer
(HPLC; equipped with an autosampler and a binary
pump), which was connected to an Agilent 6410 tandem
mass spectrometer (MS/MS) with a triple quadrupole de-
tector (Agilent Technologies, Santa Clara, CA, US) to
measure ATV calcium levels. A C18 pre-column and a
SynergiTM Fusion-RP column (4 μm, 80 Å, 50 × 2 mm;
Phenomenex, Torrance, CA, US) formed the solid phase,
whereas the mobile phase consisted of 0.03 % formic acid/
70 % acetonitrile in analytical grade water. The column
temperature was 40 °C, the flow rate 0.4 mL/min, and the
auto-sampler temperature 20 °C. The detection system
used an ESI MS/MS precursor ion (+) 559.3 m/z and a
product ion (+) 440.3 m/z. Under these conditions, inter-
day linearity was assessed by performing calibration
curves from 0.5 to 100 ng/mL (0.5, 2.5, 5, 10, 25, 50 and
100); intraday quality control was evaluated by using eight
ATV control samples of 1.7, 7.5, 35, and 75 ng/mL each.
Pharmacokinetic analysis
WinNonlin® professional software V.5.3 (Pharsight Corp.,
Mountain View, CA, US) was used for pharmacokinetic
analysis. The maximum plasma concentration (Cmax)
and the time to reach Cmax (Tmax) were calculated from
the observed concentration-time data in plasma. Phar-
macokinetic parameters were estimated with the non-
compartmental method after oral administration of a
single dose of ATV and were as follows: 1) the area
under the plasma concentration-time curve from time 0
to the time of the last measurement (AUC0-t), calculated
using the logarithmic-linear trapezoidal rule, 2) the area
under the curve from time 0 to the time extrapolated to
infinity (AUC0-∞), 3) the apparent clearance of the frac-
tion dose absorbed (Cl/F), 4) the elimination rate con-
stant in the terminal phase (Ke), and 5) the half-life in
the terminal phase of the drug (T1/2).
Statistical analyses
For sample size calculation, it was assumed that the co-
efficient of variation (CV) was 45 % for the Cmax and
AUC of ATV. Considering a significance level of 5 %, a
minimum power of 80 %, an Ω of 0.25, and a confidence
interval of 90 %, a sample size of 58 would suffice. The
metabolizer phenotypes classification was made using a
multivariate analysis of the combined pharmacokinetics
parameters Cmax and AUC0-t. To minimize the effect of
scale differences, before calculating the distance matrix,
these variables were standardized. Next, the individual
values of Cmax and AUC0-t were subjected to hierarchical
cluster analysis (HCA) using the Ward linkage method
and the interindividual Manhattan distances were com-
puted. The standardization, HCA, and the hierarchical
clustering dendogram were made using Minitab 16
demo software (Minitab Inc., State College, PA, US)
[27]. We identified the participants of each cluster and
calculated the geometric means of all pharmacokinetic
parameters of each cluster. According to the geometric
means of the pharmacokinetic parameters of the clusters
they were classified into metabolizer phenotypes. Next,
one-way ANOVA and the Kruskal-Wallis H test were
used to validate the classification model. The HWE was
determined by comparing the genotype frequencies with
the expected values using the maximum likelihood
method [28]. To detect significant differences between 2
groups, Student’s t-test or the Mann Whitney U test
were used for parametric and non-parametric distribu-
tions, respectively. Differences between more than 2
groups were assessed by one-way ANOVA or the
Kruskal-Wallis H test for parametric and non-
parametric distributions, respectively. Post hoc tests
(LSD and Tamhane’s T2) were used for pairwise compar-
isons. To evaluate the contribution of genetic factors to
the variability of the pharmacokinetic parameters linear
regression analysis was done. Possible associations be-
tween genotypes or genotype combinations and pheno-
types were assesed using contingency tables Χ2 statistics
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and Fisher’s exact tests. The linear regression analysis
and association studies were performed under three dif-
ferent models (dominant, recessive, and additive). Odds
ratios were estimated with 95 % confidence intervals.
The model for prediction was confirmed using stepwise
multiple linear regression analysis. Aforementioned ana-
lyses were performed with SPSS for Windows, V.20
(IBM Corp., Armonk, NY, US). All P-values were two-
tailed. The corrected P (Pc) values were adjusted accord-
ing to Bonferroni’s correction for multiple comparisons
and the Benajmini-Hochberg procedure was applied to




Sixty male subjects completed the study. Volunteers
were of mestizo descent, most of them students (73 %)
from the state of Nuevo Leon (83 %). Other demo-
graphic characteristics did not display significant vari-
ability (Table 1).
ATV pharmacokinetics
Despite controlling physiological and environmental
conditions the pharmacokinetic parameters were highly
variable (Table 2). The geometric mean ± SD for the
pharmacokinetic parameters obtained were: Cmax =
41.44 ± 23.35 ng/mL, AUC0-t = 141.88 ± 86.78 ng/mL*h,
AUC0-∞ = 157.12 ± 87.24 ng/mL*hr, Cl/F = 509.20 ±
265.57 L/h, T1/2 = 9.81 ± 6.58 h, and the Ke = 0.071 ±
0.035.
Classification of metabolizer phenotypes
Cmax and AUC0-t were used for HCA classification of
pharmacokinetic profiles, because Cmax tends to best re-
veal differences in pharmacokinetic profiles and AUC0-t
is considered to be the best parameter to evaluate a
drug’s interindividual pharmacokinetic variation [30].
The HCA, based on centroid distance, revealed three
main clusters. Which we identified as slow metabolizers
(30.00 %), normal metabolizers (41.66 %), and rapid
metabolizers (28.33 %), as shown in Fig. 1. The geomet-
ric means of the pharmacokinetics parameters were sig-
nificantly different among the three clusters (P ≤ 0.016),
except for T1/2 (Table 2). The mean concentration-time
profile and the geometric mean pharmacokinetic param-
eters of ATV obtained for each metabolizer phenotype
are shown in Fig. 2a and Table 2, respectively. We
observed a > 9-fold difference in ATV pharmacokinetic
paratmeters between the fastest metabolizer indivual
(Cmax = 10.94 ng/mL and AUC0-t = 55.23 ng/mL*h) and
the slowest metabolizer individual (Cmax = 101.85 ng/mL
and AUC0-t = 454.41 ng/mL*h). The distribution of phe-
notypes regarding Cmax-AUC0-t values, are presented in
Fig. 2b.
Pharmacogenetic tests
The allele and genotype frequencies of the gene poly-
morphisms with a potential impact on drug metabolism
are presented in Additional file 1. The HWE applied to
most of the gene polymorphisms, with the exception of
the gene deletions of GSTM1 and GSTT1, because the
heterozygous variants were not detected [31]. The poly-
morphism rs1800896 in the IL10 was not in HWE equi-
librium. The polymorphisms in CYP2D6, NAT2, TPMT,
and TYMS were below the call rate threshold of 0.9. The
SNPs in DPYD, rs1799807 in BCHE, and rs28399504
and rs41291556 in CYP2C19 had a MAF < 0.01. The
aforementioned polymorphisms were excluded from
subsequent analyses; a total of 30 SNPs remained for
statistical analysis.
Association between gene polymorphisms and ATV
pharmacokinetics
The various pharmacokinetic parameters were affected
differentially by the different genetic loci;i.e. a certain
polymorphism had an effect on Cmax but not on AUC0-t
or the other way round, while there were also polymor-
phisms that affected both and/or other parameters
(Table 3). The effect of MTHFR-rs1801133 on Cmax was
statistically significant. Heterozygous variant (C/T) car-
riers and homozygous variant (T/T) carriers had lower
Cmax values compared to homozygous wild-type (C/C)
carriers (P = 0.018 and 0.004, respectively). Carriers of
the variant genotype (C/T or T/T) showed significant
lower values of Cmax (P = 0.006), AUC0-t (P = 0.050) and
AUC0-∞ (P = 0.044) but statistically significant higher
values of Cl/F (P = 0.044) as compared to homozygous
wild-type subjects (C/C). The genotypes resulting from
the DRD3-rs6280 (Ser9Gly) polymorphism had a signifi-
cant impact on ATV pharmacokinetics. First, the homo-
zygous wild-type (C/C) carriers had lower T1/2 values (P
= 0.003) and higher Ke values (P = 0.008) as compared to
homozygous variant (T/T) carriers. Second, when com-
paring T/T with (C/T) genotypes, there were significant
differences for AUC0-t, AUC0-∞, Cl/F, T1/2 and Ke values
Table 1 Demographic data of volunteers
Gender BMI (kg/m2) BS (m2) Age (years) Weight (kg) Height (m) n
Mean M 23.43 1.84 24.01 70.58 1.73 60
SD 1.64 0.131 4.35 8.24 0.065
BMI body mass index; BS body surface area; M male. SD Standard Deviation. Data shown as mean (± SD)
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(P were 0.027, 0.024, 0.024, 0.027, and 0.041, respect-
ively). Third, the presence of the wild-type allele, com-
bination (C/C + C/T), had a significant influence on all
pharmacokinetics parameters (P values: Cmax = 0.050,
AUC0-t = 0.026, AUC0-∞ = 0.016, Cl/F = 0.016, T1/2 =
0.004, and Ke = 0.007). GSTM3- rs1799735 had a signifi-
cant effect on AUC0-∞ and Cl/F when *A/*A and *A/*B
were compared (P = 0.041 for both parameters). Regard-
ing TNF-rs1800629, the A allele carriers had significantly
higher AUC0-t, AUC0-∞, and T1/2 values (P = 0.035,
0.030, and 0.025, respectively) and lower Cl/F and Ke
values (P = 0.030 and 0.025). The homozygous variant
(A/A) carrier was not found. MDR1 (ABCB1) and
OATP1B1 (SLCO1B1) were the only ATV transport-
related genes with an effect on ATV pharmacokinetics.
The variant allele (T) of MDR1-rs1045642 produced a
significant increase of Cmax (P = 0.037) when the com-
bination of the heterozygous and homozygous variant
(C/T + T/T) is compared with the homozygous wild-
type (C/C). The C allele of the SLCO1B1-rs4149056
polymorphism significantly affected AUC0-t, AUC0-∞,
and Cl/F values (P = 0.004 for all three parameters) in
homozygous wild-type allele and heterozygous (C/C + C/
T) carriers. None of the other 24 polymorphisms tested
had a significant impact on ATV pharmacokinetics. The
influences of polymorphisms on the ATV pharmacokin-
etics are shown in Table 3.
Association between genotypes and metabolizer
phenotypes
No individual genotype correlated with any metabolizer
phenotype after Bonferroni’s correction for multiple test-
ing. However, MDR1-rs1045642 behavior was remark-
able in this aspect, as no homozygous wild-type (C/C)
was a slow metabolizer.
Of the six polymorphisms with an effect on ATV
pharmacokinetics, three polymorphisms associated with
the slow metabolizer phenotype considering genetic
models. The C/T or T/T genotype of MTHFR-
rs1801133, the T/T genotype of DRD3-rs6280, and the
C/T or T/T genotype of MDR1-rs1045642 were signifi-
cantly associated with slow metabolizer phenotype using
Table 2 Pharmacokinetic parameters according to metabolizer phenotype
All subjects Phenotype
Parameters Slow Normal Rapid
N 60 18 25 17
Cmax (ng/mL) 41.44 ± 23.35 75.39 ± 15.74* 40.48 ± 6.37* 22.11 ± 8.15*
AUC0-t (ng/mL*h) 141.88 ± 86.78 218.14 ± 101.90* 152.69 ± 48.83* 80.78 ± 27.24*
AUC0-∞ (ng/mL*h) 157.12 ± 87.24 231.55 ± 100.02* 166.35 ± 55.59* 95.81 ± 28.38*
Cl/F (L/h) 509.20 ± 265.57 345.49 ± 119.94* 480.93 ± 152.07* 834.97 ± 249.52*
T1/2 (h) 9.81 ± 6.58 9.64 ± 6.18 10.76 ± 7.54 8.71 ± 5.43
Ke 0.071 ± 0.035 0.072 ± 0.041* 0.064 ± 0.030* *0.080 ± 0.035
Data shown as geometric mean (± Standard Deviation)
*statistically significant (P ≤ 0.016)
Fig. 1 Classification of ATV metabolic phenotypes. A dendrogram generated with the Manhattan distance and Ward’s linkage method illustrates
rapid metabolizers (red), normal metabolizers (green), and slow metabolizers (blue)
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dominant, recessive, and dominant models, respectively.
This association remained statistically significant after
adjusting for multiple testing using Bonferroni’s correc-
tion (P < 0.05; Table 4).
Linear regression analysis using aforementioned gen-
etic models confirmed that these five polymorphisms af-
fected the variability of pharmacokinetic parameters of
ATV, except for the TNF-rs1800629 polymorphism
(Additional file 2).
Next, we analyzed genotype combinations of the six
polymorphisms that individually had a significant effect
on ATV pharmacokinetic parameters (Table 3 and
Additional file 3): cluster A (subjects with genotypes re-
lated to normal metabolism), cluster B (subjects with
only 1 genotype related to decreased metabolism), and
cluster C (subjects with 2 or more genotypes related to
decreased metabolism). As the MTHFR, MDR1, and
DRD3 genotypes effected pharmacokinetics most, clus-
ters that only considered these genes were formed: Clus-
ter D (subjects with MTHFR, MDR1 and DRD3
genotypes related to normal metabolism), cluster E (sub-
jects in which either MTHFR, MDR1 or DRD3 gentoype
related to decreased metabolism), and cluster F (subjects
in which all MTHFR, MDR1 and DRD3 genotypes were
related to decreased metabolism). The analysis of geno-
type combinations revealed that cluster C, i.e. subjects with
2 or more genotypes related to decreased metabolism, had
a significant higher Cmax (P ≤ 0.016), AUC0-t (P ≤ 0.011)
and AUC0-∞ (P = 0.011), but significantly lower Cl/F values
(P = 0.011) when compared with cluster A and B. The
genotype combination analysis limited to MTHFR, MDR1
and DRD3 showed that cluster F was significantly different
from clusters D and E; a higher Cmax (P = 5.3 × 10
−5),
AUC0-t (P = 3.61 × 10
−4), and AUC0-∞ = (4.22 × 10
−4), but
lower Cl/F (P = 1.35 × 10−4). The influences of the clusters
on ATV pharmacokinetics are shown in Table 3.
The association analysis between clusters and pheno-
types displayed a mutual dependency and association
(P ≤ 0.05). The C and F cluster were associated with slow
metabolizers as shown in Table 5. The stepwise multiple
regression analysis showed that the combination of
MTHFR, DRD3 and MDR1 polymorphisms are related
to ATV slow metabolizers. The combination of these
three polymorphisms contributed to the pharmacoki-
netic variability prediction with an R2 = 0.295, and ad-
justed R2 = 0.257 with a P = 2.26 × 10−4.
Adverse effects
ATV was well tolerated by all subjects, since no volun-
teer showed any adverse effects during and at the end of
the pharmacokinetic study. No clinically significant
changes from baseline were observed in the physical
examination or the ECG during the study, and no clinic-
ally significant mean changes from baseline were ob-
served for any laboratory parameters.
Fig. 2 Distinctive pharmacokinetic profiles of rapid, normal and slow metabolizers. a Mean peak plasma ATV concentration-time curves after a
single 80-mg dose of ATV of the three metabolizer phenotypes. Data shown are mean ± standard error (SE) concentrations. b Distributions of
metabolizer phenotypes with regard to Cmax-AUC0>-t values. For both a xand b: rapid metabolizers in red, normal in green, and slow ones in blue
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Discussion
Numerous studies have been performed to better
characterize the high variability in ATV pharmacokinetic
parameters. In this study, the maximum and minimum
Cmax and AUC0-t values differed by approximately 10-
folds in 60 healthy volunteers. Other studies even ob-
served 15-folds for the Cmax and 12-folds for AUC, after
a single dosis of ATV [32]. The interindividual variability
exists even though the study subjects are under con-
trolled conditions. Actually, the search of prediction bio-
markers for disease risk and the response to treatment is
an area of research with great activity. However, so far
no pharmacogenetic testing in clinical studies have been
carried out in Mexicans. To contribute to the identifica-
tion of the genetic architecture underlying the drug me-
tabolism and response in the Mexican population, we
Table 3 Polymorphisms and genotype clusters with significant effect on ATV pharmacokinetics
Pharmacokinetics parameters
Genotypes N Cmax (ng/mL) AUC0-t (ng/mL*h) AUC0-∞ (ng/mL*h) Cl/F (L/h) T1/2 (h) Ke
MTHFR rs1801133
C/C 14 60.46 ± 20.60 195.77 ± 91.84 213.25 ± 94.16 448.86 ± 202.58 12.95 ± 9.30 0.07 ± 0.04
C/T 37 44.81 ± 24.32* 152.83 ± 87.67 166.43 ± 86.52 595.20 ± 274.47 10.78 ± 5.84 0.08 ± 0.04
T/T 9 34.89 ± 12.90** 141.64 ± 66.29 151.57 ± 67.28 623.70 ± 287.68 9.94 ± 4.19 0.08 ± 0.03
C/T + T/T 46 42.87 ± 22.77§ 150.64 ± 83.37§ 163.52 ± 82.64§ 600.77 ± 274.06§ 10.62 ± 5.52 0.08 ± 0.03
DRD3 rs6280
C/C 17 39.90 ± 14.47 149.50 ± 59.86 159.43 ± 57.99 562.72 ± 200.54 8.63 ± 2.33¢ 0.08 ± 0.02¢
C/T 26 44.12 ± 23.77 143.60 ± 85.50 156.77 ± 86.61 654.34 ± 316.38 10.67 ± 6.65 0.09 ± 0.04
T/T 17 58.41 ± 26.70# 199.72 ± 102.65§§, # 218.89 ± 100.70§§, # 431.78 ± 177.83§§, # 14.44 ± 8.15§§, # 0.06 ± 0.03§§, #
C/C + C/T 43 42.45 ± 20.51 145.93 ± 75.66 157.83 ± 75.82 618.12 ± 277.41 9.86 ± 5.43 0.09 ± 0.04
GSTM3 rs1799735
*A/*A 55 44.71 ± 21.36 158.00 ± 89.57 171.60 ± 90.03 582.27 ± 270.90 10.92 ± 6.24 0.08 ± 0.03
*A/*B 5 71.92 ± 32.15 196.08 ± 33.24 213.93 ± 28.26¥ 378.87 ± 46.77¥ 13.82 ± 10.17 0.08 ± 0.07
TNF rs1800629
G/G 51 45.54 ± 22.80 153.18 ± 82.16 167.14 ± 83.12 586.66 ± 266.42 10.59 ± 6.14 0.08 ± 0.04
G/A 9 55.88 ± 26.94 215.85 ± 96.68€ 230.57 ± 93.37€ 391.55 ± 132.91€ 14.66 ± 8.45€ 0.06 ± 0.02€
MDR1 rs1045642
C/C 13 33.43 ± 13.40 135.68 ± 78.72 150.53 ± 79.10 699.77 ± 376.59 10.87 ± 4.99 0.08 ± 0.04
C/T + T/T 47 50.78 ± 24.21¤ 168.22 ± 88.36 181.93 ± 88.95 528.14 ± 216.66 11.24 ± 7.00 0.08 ± 0.03
SLCO1B1 rs4149056
C/C + C/T 11 53.92 ± 24.72 222.27 ± 91.48 241.23 ± 92.98 390.51 ± 195.46 12.42 ± 8.59 0.07 ± 0.03
T/T 49 45.41 ± 23.01 147.45 ± 80.40≠ 160.29 ± 79.55≠ 604.57 ± 264.87≠ 10.88 ± 6.12 0.08 ± 0.04
P-values of genotype combinations on ATV pharmacokinetics
Clusters Cmax AUC0-t AUC0-∞ Cl/F T1/2 Ke
A vs. B 0.163 0.060 0.041£ 0.041£ 0.519 0.519
B vs. C 0.007£ 4 × 10−4£ 0.001£ 0.001£ 0.177 0.177
A vs. C 0.016£ 0.011£ 0.011£ 0.011£ 0.181 0.181
C vs. A + B 0.001£ 9.1 × 10−5£ 1.31 × 10−4£ 9.5 × 10−5£ 0.112 0.399
D vs. E 0.187 0.060 0.041£ 0.002£ 0.610 0.486
E vs. F 2.3 × 10−4£ 0.001£ 0.001£ 0.004£ 0.241 0.260
D vs. F 1 × 10−3£ 0.014£ 0.011£ 6 × 10−6£ 0.230 0.177
F vs. D + E 5.3 × 10−5£ 3.61 × 10−4£ 4.22 × 10−4£ 1.35 × 10−4£ 0.115 0.176
Data presented as mean ± standard deviation
*P = 0.018 (C/T vs. C/C), **P = 0.004 (T/T vs. C/C), §P ≤ 0.050 (C/T + T/T vs. C/C), §§P ≤ 0.041 (T/T vs. C/T), ¢P ≤ 0.008 (C/C vs. T/T), #P ≤ 0.050 (T/T vs. C/C + C/T), ¥P = 0.041
(*A/*B vs. *A/*A), €P ≤ 0.035 (G/A vs. G/G), ¤P = 0.037 (C/T + T/T vs. C/C), ≠P = 0.004 (T/T vs. C/C + C/T), £ = significant. Clusters are explained in the main text
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Table 4 Association values between genotypes and metabolizer phenotypes
Association values between genotypes and the slow metabolizer phenotype using dominant, recessive and additive models
Gene Polymorphism Model OR (95 % CI) P-Value Pc Value
MTHFR rs1801133 Dominant (C/C vs. C/T + T/T) C/T + T/T = 0.64 (0.42–0.99)* 0.011 0.028**
C/C = 3.11 (1.26–7.68)*
DRD3 rs6280 Recessive (C/C + C/T vs. T/T) C/C + C/T = 0.62 (0.38–1.00) 0.015 0.034**
T /T = 2.63 (1.21–5.70)*
GSTM3 rs1799735 Additive (*A/*A vs. *A/*B) *A/*A = 0.88 (0.70–1.09) 0.126 0.308
*A/*B = 3.50 (0.64–19.20)
TNF rs1800629 Additive (G/G vs. G/A) G/G = 0.89 (0.68–1.16) 0.324 0.553
G/A = 1.82 (0.55–6.00)
MDR1 rs1045642 Dominant (C/C vs. C/T + T/T) C/T + T/T = 1.45 (1.18–1.77)* 0.008 0.020**
C/C = 0.06 (0.003–1.00)
SLCO1B1 rs4149056 Recessive (C/C + C/T vs. T/T) C/C + C/T = 1.33 (0.45–3.99) 0.610 0.884
T/T = 0.93 (0.70–1.23)












examined the impact of 30 polymorphisms in genes re-
lated to drug metabolism and response on ATV
pharmacokinetics.
In this study, we propose a novel and simple approach
to classify the metabolizer phenotypes from the analysis
of pharmacokinetic profiles. This approach uses Cmax,
which reflects the absorption rate, and the AUC0-t) that
reflects the extent of absorption and clearance. We dis-
tinguished three different metabolic phenotypes (slow,
normal, and rapid) with significant differences for phar-
macokinetic parameters (Table 2). The slow phenotype
displayed the highest variability in pharmacokinetic
parametes, clearly illustrated by the greater dispersion of
Cmax-AUC0-t valuesof the slow metabolizers as com-
pared to the normal and rapid ones. T1/2 behaves sto-
chastically, and its variance increased with the time,
which may be the reason that there is no significant T1/2
difference among metabolizer phenotypes. Our pheno-
type classification is consistent with the one reported by
Quing Huang et al., who used a pharmacometabonomic
approach to classify 48 healthy volunteers as low,
medium, and high ATV metabolizers [32]. Slow metabo-
lizers tend to have higher plasma drug levels and to be
more susceptible to adverse side effects. On the other
hand, rapid metabolizers tend to have lower plasma drug
levels, which may explain a poor drug response. Our re-
sults support the use of this classification method for in
vivo studies.
There was a significant effect of six gene polymor-
phisms on different pharmacokinetics parameters (P ≤
0.05). T allele carriers of MTHFR-rs1801133 had a lower
Cmax and AUC but increased Cl/F. This pharmacokinetic
profile is consistent with increased clearance activity and
a lower ATV concentration in the body, which may lead
to a weaker response to ATV.
To our knowledge, our study is the first that reports
an effect of the MTHFR-rs1801133 polymorphism on
statin pharmacokinetics, and is consistent with previous
studies on drug response and cardiovascular disease sus-
ceptibility. In 2008, Maitland-van der Zee et al. found
that the MTHFR-rs1801133 C/C genotype protects
against coronary heart disease in different populations
[33]. Another study reported that the C/C genotype
protected against cardiovascular disease in a Turkish
population under statin therapy [34]. The C allele fre-
quencies reported in both studies [33, 34] are different
from the allele frequencies found in the Mexican popu-
lation. The MTHFR-rs1801133 polymorphism (C677T)
causes an Ala→Val substitution which decreases en-
zyme activity leading to increased homocysteine levels.
Hyperhomocysteinemia is a known risk factor for car-
diovascular disease [34]. How the T variant of MTHFR-
rs1801133 augments ATV clearance, so that the drug re-
sponse is diminished, remains to be elucidated.
With respect to the DRD3-rs6280 (Ser9Gly) poly-
morphism, the homozygous variant genotype (T/T) af-
fected the pharmacokinetic parameters consistent with a
slow metabolizer phenotype. So far, the influence of
DRD3-rs6280 on ATV pharmacokinetics has not been
reported. DRD3 encodes a dopamine receptor and is
functionally related to reward stimuli and control of
movement [35]. DRD3-rs6280 polymorphisms have been
mainly related to addictive behavior[36, 37] and involun-
tary movements [38]. The C allele is related to a stron-
ger intracellular response to dopamine [35]. However,
another DRD3 polymorphism (rs1486012) has been as-
sociated with a decrease in lopinavir/ritonavir elimin-
ation [39].
Subjects that carry the *B allele of GSTM3-rs1799735
had a decreased clearance of ATV and therefore an in-
creased AUC0-∞. These results are not consistent with
the higher detoxification activity associated with the *B
allele [40] of this gene which encodes a glutathione S-
transferase M3 that conjugates glutathione with sub-
strates like drugs, toxins, and carcinogens. The *B allele
represents a 3-bp deletion in intron 6, which generates a
recognition sequence for the Ying Yang transcription
factor (YY1), and thus alters the gene expression of
GSTM3. We found no previous report relating this poly-
morphism to statin metabolism. The reason for the lack
of association of the GSTM3 polymorphism with the
metabolic phenotypes may be due to the low frequency
of the *B allele in our relatively small study group.
GSTM3-rs1799735 has been associated with various
types of cancers with different effects [40–42]. Allele fre-
quencies found for rs1799735 are similar to those
Table 5 Association values between genotypes and metabolizer phenotypes
Association between genotype combinations and metabolizer phenotypes
Clusters Phenotypes OR (95 % CI) P-Value Pc Value
A, B, C Rapid, Normal, Slow - 1 × 10−3** 3.1 × 10−3**
C, A + B Slow, Normal + Rapid 4.00 (1.39–11.49)* 3.83 × 10−4** 1 × 10−3**
D, E, F Rapid, Normal, Slow - 6.6 × 10−5** 1.6 × 10−3**
F, D + E Slow, Normal + Rapid 4.53 (1.62–12.68)* 7 × 10−6** 2.9 × 10−5**
OR odds ratio, CI confidence interval, Pc P-values adjusted by using Bonferroni’s correction for multiple comparisons, − = Not calculated, ** = P ≤ 0.05. Clusters are
explained in the main text
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reported by Jain et al. [42]. Nevertheless, the homozy-
gous variant (*B/*B) carrier was absent in our sample.
Heterozygous A allele carriers of TNF-rs1800629 had
pharmacokinetic parameters that were consistent with a
diminished clearance of ATV. Nevertheless, their influ-
ence on ATV pharmacokinetic variability was not con-
firmed by linear regression analysis. The rs1800629 (G/
A) polymorphism is located in the promoter region of
TNF. TNF encodes the pro-inflammatory cytokine
tumor necrosis factor alpha. The variant A allele in-
creases protein expression; therefore the wild-type G al-
lele has a protective effect by reducing the risk of
thrombosis in patients with hemodialysis [43]. It is un-
known how TNF is involved in ATV metabolism, but
there is evidence that ATV may attenuate TNF expres-
sion [44], which results in a reduction of the inflamma-
tory process. The allele and genotype frequencies in our
study group are similar to those of a Turkish population
[43].
Previous studies have reported that the MDR1-
rs1045642 polymorphism affects the response to ATV
treatment. However, different studies disagree with re-
spect to which homozygous genotype results in a better
response to therapy [45–47]. MDR1 encodes a P-
glycoprotein transporter, that functions as an ATP-
dependent efflux pump and thus protects against harm-
ful substances. MDR1 is widely expressed, for example
in the small intestine, the blood–brain barrier, hepato-
cytes, and kidney proximal tubules [48, 49]. The MDR1-
rs1045642 (C3435T) polymorphism is located in exon
26 of the MDR1/ABCB1 at a wobble position that does
not produce an amino acid change. However, Hoffmeyer
et al. [48] have reported that subjects homozygous for
the variant (T/T) not only had reduced expression of
MDR1 but also higher drug plasma levels as compared
to subjects homozygous for the wild-type (C/C) [48]. In
our study, carriers of the variant T allele, either homozy-
gous or heterozygous, had a higher Cmax. Similar results
were found by Zhou et al. [50] and Gonzalez-Vacarezza
et al. [51] on fluvastatin and quetiapine pharmacokinet-
ics, respectively. The T allele and genotype frequencies
found in our study group were similar to those reported
in the Lahu population (0.54) [52], the Dutch population
(0.52) [53], and in Caucasians (0.53) [54]; however, they
differ from those found in the Chilean population (0.34)
[16], the African population (0.17), and in African-
Americans (0.39) [55].
Similar to MDR1 polymorphisms, there are conflicting
reports about the response and adverse drug reactions
to statins in subjects with the SLCO1B1-rs4149056
(SLCO1B1*5) polymorphism [47, 56]. SLCO1B1, which
is highly expressed in the liver, encodes an organic anion
influx pump for numerous compounds. The SLCO1B1-
rs4149056 (c.T521C) polymorphism results in the
substitution of alanine for valine at amino acid residue
174, which reduces transport activity and leads to higher
circulating statin concentrations that could be respon-
sible for the reported adverse effects [57]. Our results
support that rs4149056 affects ATV pharmacokinetics.
However, the polymorphism did not associate with
metabolic phenotypes. This could be due to the low fre-
quency of C allele carriers in our sample. The variant T
allele is the most frequent in Mexican population.
In summary, in our study we found six polymorphisms
in different genes that have a significant effect on the
pharmacokinetics of ATV. GSTM3 is a phase II metab-
olizing enzyme, which explains its impact on clearing
parameters (Cl/F), and as a consequence AUC. MDR1
and SLCO1B1 are transporters, and this function may
explain their impacton ATV pharmacokinetic parame-
ters (Cmax, AUC, and Cl/F). However, the significant im-
pact of the DRD3, MTHFR, and TNF polymorphisms on
ATV Cmax, AUC’s, Cl/F T1/2, and Ke is achieved by so
far unknown mechanisms.
The value of a pharmacokinetic parameter is the end
result of a complex ADME process that involves many
proteins. Polymorphisms in the different encoding genes
may neutralize each other, which makes it highly
unlikely that a single polymorphism determines a
metabolizer phenotype. However, a slow metabolizer
phenotype may be the result of various polymorphisms
that reinforce a certain impact. Indeed the accumulation
of polymorphisms of the six genes (MTHFR, GSTM3,
DRD3, TNF, MDR1, and SLCO1B1) coincided with a
shift from rapid metabolizers (no genotypes related to
decreased metabolism in cluster A) to slow metabolizers
(cluster C, up to six polymorphisms). MTHFR, MDR1
and DRD3 polymorphisms seem to have a leading im-
pact on metabolizer phenotype, and were sufficient to
identify slow metabolizers in our study group. For ex-
ample, cluster D, comprised of MTHFR, MDR1 and
DRD3 wild-type genotypes, were rapid metabolizers;
cluster E is a mixture of the rapid and normal metaboli-
zers, whereas the accumulation of these three polymor-
phisms (cluster F) is sufficient to identify slow
metabolizers. These results were confirmed by associ-
ation tests with different models, and stepwise multiple
regression analysis. The interference of other genes in
the A and B clusters may explain the lack of association
with the rapid metabolizer phenotype. This can be ex-
plained by the complexity of the process that underlies
the pharmacokinetic parameters, which involves many
genes and other environmental factors. Thus, if a gene
variant has a relatively small impact it will not be de-
tected. The distribution plot (Fig. 2b) illustrates that
slow metabolizer phenotype accumulates the widest vari-
ability of polymorphisms. Although we found six poly-
morphism with effect on the ATV pharmacokinetics, we
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know that the variability is not limited to the presence
of these six markers, since other polymorphisms with lit-
tle or moderate influence and not analyzed in this study,
could contribute to the observed variability in each
metabolic phenotype.
To our knowledge, this is the first report on the use of
a massive genotyping tool (microarrays) to associate
gene polymorphisms with pharmacokinetic variability of
a drug commonly used by the Mexican population. The
pharmacokinetic variability of ATV depends on several
factors, including genetic factors. We identified six poly-
morphisms on six different genes that, individually, had
an impact on some or all pharmacokinetic parameters.
Absence of all polymorphism corresponded to rapid
metabolizers, whereas the accumulation of polymor-
phisms caused a shift to slow metabolizers. However,
some shortcomings existed in our study. First, there
were insufficient data to correlate the metabolic pheno-
types with the ATV response. Second, the number of
participants was not large enough to validate our find-
ings. Hence, our findings need to be validated in a larger
population with genotype preselection. In order to iden-
tify (a set of ) candidate predictors for ATV metabolizer
phenotype, confirmative studies should be performed
that focuse on the identified six polymorphisms. Our re-
sults may also be considered for future meta-analysis.
The ultimate aim is that a pharmacogenetic analysis of a
set of genes can be used to guide a personalized dosage
that ensures drug response and prevents adverse drug
effects.
Conclusions
In summary, this pilot study offers a novel, comprehen-
sive approach to understand the genetic contribution to
the variability of ATV metabolism in a Mexican popula-
tion. It enabled the identification of candidate predictive
biomarkers for slow ATV metabolizers. The future con-
firmation of the predictive potential of these candidate
genetic biomarkers and their incorporation in routine
genotyping tests may optimize ATV efficacy in the clin-
ical practice.
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